Who actually manufactures an Indian semaglutide brand? A company name printed on an advertisement can identify a manufacturer, licensing partner, contract supplier or marketer. Those roles are not interchangeable. India’s 2026 launches are particularly instructive: some manufacturers introduced their own semaglutide products, while Zydus supplied one reusable-pen platform through several separate brand and marketing relationships.
This guide traces primary company announcements rather than generating a list of supposed factory locations from product catalogs. Dr. Reddy’s described in-house API and formulation development for Obeda; Sun Pharma positioned Noveltreat and Sematrinity as separate brands; Alkem and Glenmark described specific product formats; Lupin and Torrent disclosed contractual relationships with Zydus. For trade-name identification rather than corporate roles, visit Indian semaglutide brands.
All products discussed here relate to the Indian market. None should be represented as a U.S.-approved generic semaglutide solely because its maker operates internationally or has other FDA-inspected facilities. The U.S. FDA product directory and foreign-product import guide address a different regulatory question.
An API developer works on the active pharmaceutical ingredient; a formulation developer creates the finished presentation; a manufacturer or contract manufacturer produces at a specified site; a distributor and marketer promote or supply a product under a trade name. One corporate group may perform several roles, but a licensing agreement can deliberately split them across unrelated companies.
A responsible directory states only those roles documented in company disclosures. Even a statement that a company has launched a product does not automatically identify the specific factory responsible for every batch. Search results sometimes conflate a familiar Indian pharmaceutical company with the maker of a named product, especially when the local marketing label is most visible.
Dr. Reddy’s March 21, 2026 SEC-filed announcement described Obeda as its DCGI-approved semaglutide injection for type 2 diabetes in India. The company explicitly stated that API development and manufacturing, along with formulation development, were conducted in-house. It introduced disposable pre-filled pen presentations described as 2 mg and 4 mg total strengths.
That announcement is strong evidence of the company’s claimed development and production role. It is not a complete public batch-by-batch factory list, a confirmation of foreign regulatory approval or evidence that an individual merchant is selling an authorized product today. Our Obeda profile focuses on the brand and its actual pen identity.
Sun Pharma announced Noveltreat for chronic weight management and Sematrinity for type 2 diabetes in March 2026. Its earlier DCGI disclosures distinguished the approvals underlying those uses. This is one corporate portfolio with product- and indication-specific labeling, not proof that both trade names share identical prescribing directions or every presentation.
The brand distinction matters more to buyers than a generic statement that Sun is a multinational manufacturer. Read Noveltreat for the weight-management product and Sematrinity for the diabetes product. Neither Indian authorization should be transferred to U.S. Wegovy or Ozempic labeling.
Zydus described a 15 mg/3 mL semaglutide cartridge used with a reusable pen. Its March 17 licensing agreement with Lupin provided for Zydus technology to be co-marketed as Semanext and Livarise, while Zydus would promote Semaglyn, Mashema and Alterme. On March 18, Zydus and Torrent disclosed that Zydus would manufacture and supply a related product marketed by Torrent as Sembolic.
The two agreements are documentary evidence that Zydus is the originating formulation partner while Lupin and Torrent hold brand-specific marketing arrangements. Listing all of those labels as independent manufacturers would be inaccurate. The Semaglyn profile covers the platform; Semanext covers the Lupin relationship.
Lupin’s March 17 press release describes rights to co-market Zydus semaglutide in India under Semanext and Livarise, including license and supply terms. Torrent’s March 18 announcement states it will promote Sembolic under its own brand with Zydus manufacturing and supplying the product. These are explicit role assignments, which should take precedence over broad company descriptions.
A reader comparing Semaglyn, Semanext and Sembolic is comparing distribution and trade-name identities within a disclosed product family, not necessarily three separate clinical trials or unique substances. We do not infer a different efficacy profile or FDA status from the identity of the marketer.
Alkem’s March 21, 2026 release introduced semaglutide injection under three trade names: Semasize, Obesema and Hepaglide. It also described disposable pre-filled pens for initial offerings and a reusable pen format for higher maintenance presentations. The company stated it had DCGI approval for type 2 diabetes and chronic weight management in India.
These documented sister names belong together rather than requiring multiple nearly identical SEO pages. Semasize serves as the representative family page, clarifying what the corporate notice proves and which details would need original packaging or separate authorization records before being asserted.
Glenmark announced GLIPIQ for type 2 diabetes in India on March 21, 2026. Its release is unusually specific about presentations: multi-dose vials used with dose-specific syringes and pre-filled pens, with labeled product concentrations detailed in the manufacturer notice. The release also refers to Indian CDSCO approval following a comparative Phase III study.
Because the vial and pen are distinct device configurations, the GLIPIQ product page has substantial technical identification value. The announcement does not authorize unsupported claims about U.S. availability, the manufacturer of each component or dose conversion between device systems.
Natco has appeared in reporting on Indian semaglutide products such as Semanat. However, a U.S. FDA warning letter addressed to a specific online seller offering Semanat is not, by itself, a finding that Natco as a manufacturer committed the seller’s violations. Distinguish the brand, the seller and the authority issuing the document.
We retain Natco as part of the manufacturer landscape without manufacturing-site claims or a dedicated checkout. The regulatory distinction is explored on imported semaglutide. Similarly, approval of any other product from a company with a U.S. business does not approve its India-only semaglutide brand.
Start with a dated regulatory filing or manufacturer announcement that names both parties and specifies whether the agreement is for manufacturing, supply, licensing or marketing. Then check whether the brand has its own finished-dose presentation or shares an existing cartridge and device platform. Avoid assigning a manufacturing facility address when only the company’s registered office is available.
If you need U.S. purchase information, this relationship chart is not a substitute for FDA product verification, a valid prescription or a licensed pharmacy. The U.S. purchasing guide intentionally covers authorized U.S. channels rather than foreign company marketing networks.
An Indian supply agreement can identify the manufacturer and marketer of a product but cannot create a U.S. product approval. Zydus licensing news, for example, explains who supplies the formulation and who sells under local trade names; it should not be copied into an American online pharmacy advertisement as evidence that the foreign brand is an authorized generic.
A separate regulatory approval and legally licensed dispensing channel are needed for U.S. access. The U.S. generic-approval explainer and pharmacy-verification checklist cover those different questions.
Interpret the rows as documented contractual or production roles, not a catalog of manufacturers with independently confirmed plant addresses. For Zydus-linked products, distinguish original formulation development and reusable-device supply from Lupin or Torrent marketing under their own brand names. For Dr. Reddy’s, differentiate the company’s stated in-house API and formulation work from any unverified individual batch factory.
If a claimed supply relationship has no release, license, filing or label identifying the parties, record the role as unverified. Corporate marketing, production capability and FDA approval are three different questions, especially where a company has numerous products approved in other countries.
| Company | Brand or family | Role documented in source | Announcement date |
|---|---|---|---|
| Dr. Reddy’s | Obeda | In-house API and formulation claim | March 21, 2026 |
| Sun Pharma | Noveltreat; Sematrinity | Company brand development/launch | March 21, 2026 |
| Zydus | Semaglyn; Mashema; Alterme | Formulation platform and manufacturing/supply | March 17–18, 2026 |
| Lupin | Semanext; Livarise | Licensee/co-marketer of Zydus product | March 17, 2026 |
| Torrent | Sembolic | Co-marketer; Zydus supplying | March 18, 2026 |
| Alkem | Semasize; Obesema; Hepaglide | India launch and pen formats | March 21, 2026 |
| Glenmark | GLIPIQ | Vial and pen product company | March 21, 2026 |
This corporate map documents who is publicly identified as API developer, formulation originator, supplier or marketer in the Indian semaglutide market. It is not evidence that every promoted brand was manufactured at the marketing company’s own factory. Primary company statements establish only the specific roles they actually describe; ongoing supply and plant-level batch information require independent verification.
Information about Dr. Reddy’s, Sun Pharma, Alkem, Glenmark and the Zydus–Lupin and Zydus–Torrent arrangements was evaluated against dated 2026 first-party material. No India-market trade name here is presented as an FDA-approved U.S. generic, an available U.S. prescription or a lawful imported purchase option. Commercial referrals, if displayed elsewhere, must be labeled independently of these editorial findings.
No. Licensing and co-marketing arrangements can separate the formulation manufacturer from the brand marketer.
The March 17, 2026 Lupin–Zydus announcement describes Semanext as a co-marketed version of Zydus semaglutide technology.
Zydus retained its own trade names and entered separate licensing and co-marketing arrangements with Lupin and Torrent.
No. Sun Pharma announced them for different Indian therapeutic positioning; their specific approved uses must be checked separately.
Its March 21 announcement describes in-house API and formulation development and manufacturing, without publishing a comprehensive batch-specific factory register.
Alkem Laboratories introduced Semasize, Obesema and Hepaglide in its March 21, 2026 India launch notice.
Glenmark’s March 21 statement describes both vials and pre-filled pens for its Indian semaglutide brand.
No. Product approval is separate from a facility inspection or a company’s international operations.
No. Prices, promotional terms and stock change; this directory focuses on verified company roles and product identity rather than retail rankings.